Ετικέτες

Κυριακή 17 Οκτωβρίου 2021

Head and Neck Malignant Paragangliomas: Experience from a Single Institution

xlomafota13 shared this article with you from Inoreader

pubmed-meta-image.png

Ear Nose Throat J. 2021 Oct 15:1455613211052338. doi: 10.1177/01455613211052338. Online ahead of print.

ABSTRACT

Objectives: To summarize the clinicopathological and genetic features of malignant paragangliomas in head and neck cancer and to explore the appropriate treatment options for this rare lesion. Methods: Six patients harboring head and neck malignant paraganglioma from Beijing Tongren Hospital were retrospectively reviewed. The clinicopathological char acteristics, gene mutations, and prognosis of these patients were analyzed. Results: Of these 6 patients, 3 were male and 3 were female; 4 patients harbored malignant carotid body tumors, and two had malignant vagal paragangliomas. Three patients had cervical lymph node metastasis, two presented with lung and bone metastasis, and 1 had lung and liver metastasis. Of the 6 patients, four underwent surgical resection, and the other two patients denied surgery and instead received chemotherapy with paclitaxel, ifosfamide, and dacarbazine. These 2 patients with vagal paraganglioma received postoperative radiotherapy. All 6 patients are still alive at the present time, with a median follow-up time of 66 months. Positive Ki-67 expression in tumor tissue ranged from 1% to 40%. Genetic mutations in SDHD, SDHB, ATR, and MAP3K13 were identified in 4 patients. Conclusions: After comprehensive treatment, head and neck malignant paraganglioma can attain a favorable prognosis. Geneti c mutations are commonly detected in patients with malignant paragangliomas. This study also identified mutations in ATR and MAP3K13 in these patients.

PMID:34654328 | DOI:10.1177/01455613211052338

View on the web

Coblation supraglottoplasty: a ten-year experience in a tertiary referral hospital

xlomafota13 shared this article with you from Inoreader

Eur Arch Otorhinolaryngol. 2021 Oct 16. doi: 10.1007/s00405-021-07130-8. Online ahead of print.

ABSTRACT

PURPOSE: The present study aims to review the outcomes of coblation supraglottoplasty performed for children with different types of laryngomalacia, and we discuss the factors affecting these outcomes.

METHODS: We retrospectively reviewed the medical records of laryngomalacia patients admitted to the Otorhinolaryngology Department, Mansoura University, from 2010 to 2020. We examined the patient's demography, symptoms, comorbidities, type of laryngomalacia, oxygen saturation, and final outcomes.

RESULTS: Our study included 235 patients; 122 patients responded to medical therapy, while 113 underwent surgical management. There is a significant relation between the types and therapy they underwent (p ≤ 0.001). Larger percentage within type I underwent medical therapy. There is a statistically significant difference between the studied groups regarding age at surgery. On pairwise comparison, patients with type II had the lowest age significantly at the surgery when compared with each other individual group (p ≤ 0.001). On multivariate regression analysis, the presence of comorbid congenital heart disease, neurological comorbidities significantly increased the risk of failure of surgical intervention by 17.32 and 5.803 folds, respectively.

CONCLUSIONS: Coblation supraglottoplasty is effective and safe to treat severe laryngomalacia. Different morphological types of laryngomalacia require slight surgical variations of coblation supraglottoplasty. The presence of comorbid congenital heart disease, neurological comorbidities significantly increased the risk of failure of surgical intervention.

PMID:34654950 | DOI:10.1007/s00405-021-07130-8

View on the web

Preclinical Implementation of a Steerable, Da Vinci Xi ® Compatible CO2‐Laser Fiber Carrier for Transoral Robotic Surgery (TORS): a Cadaveric Feasibility Study

xlomafota13 shared this article with you from Inoreader

Abstract

Introduction

Monopolar electrocautery is the most common dissection and coagulation tool during transoral robotic surgery (TORS) but causes significant collateral tissue damage as opposed to CO2 laser. We aimed at combining both modalities in one robotic instrument arm.

Methods

We developed a steerable CO2-laser fiber carrier serving as an add-on to the existing Endowrist® monopolar spatula of the Da Vinci Xi. Feasibility and safety were assessed in a preclinical setting.

Results

One radical tonsillectomy with monopolar cautery and 3 with the instrument prototype were performed in 2 cadavers by 2 surgeons. No serious prototype-related intra-operative difficulties were observed. Safe and efficient switching between energy sources proved possible in all simulated intra-operative bleeding events. Prototype use allowed for the identification of the majority of key anatomical structures and was scored favorably on NASA-TLX ques tionnaires.

Discussion

The reported prototype successfully combines the advantages of CO2-laser with the advantages of TORS.

This article is protected by copyright. All rights reserved.

View on the web

The clinical and financial impact of introducing robotic‐assisted hysterectomy in a tertiary referral center: a direct cost analysis of consecutive hysterectomies during a decade

xlomafota13 shared this article with you from Inoreader

Abstract

Background

Economic data and the clinical impact of introducing robotic-assisted hysterectomy in a European setting are scarce with conflicting findings.

Methods

In this retrospective cohort study, the cost and complication rate of the different approaches of hysterectomy are investigated, both benign and (pre)malignant indications were included.

Results

844 patients were included: 323 (38.3%) patients underwent robotic-assisted hysterectomy (RAH), 317 (37.5%) total abdominal hysterectomy (TAH), and 204 (24.2%) total laparoscopic hysterectomy (TLH). TAH dropped from 67.2% to 25.5% of procedures, whilst RAH rose to 41.8% of cases. The total hospitalization cost was for RAH €5208.39 (± €916.91), for TAH €5846.61 (± €4464.37) and for TLH €3790.06 (± €1267.05). The postoperative complication rate of TAH (9.1%) was significantly higher in comparison with TLH and RAH (5.4% and 3.1% respectively, p=0.005).

Conclusions

RAH h as replaced TAH in most cases, especially for large uteri, early-stage endometrial cancer and in selected endometriosis cases, resulting in reduced morbidity with lower hospitalization costs. The indications for TLH remained, including menorrhagia, adenomyosis and persistent cervical dysplasia.

This article is protected by copyright. All rights reserved.

View on the web

Long-term swallowing-related outcomes in oral cancer patients receiving proactive swallowing therapy

xlomafota13 shared this article with you from Inoreader

pubmed-meta-image.png

Oral Oncol. 2021 Oct 13;122:105569. doi: 10.1016/j.oraloncology.2021.105569. Online ahead of print.

ABSTRACT

OBJECTIVES: The present study aimed to evaluate the impact of proactive swallowing rehabilitation on swallowing function and quality of life (QoL) in oral cancer patients in the first two years after definitive treatment.

MATERIALS AND METHODS: Consecutive adult patients with locally advanced oral cancer who received radical surgery, free flap reconstruction, and adjuv ant radiotherapy were recruited prospectively, to whom proactive swallowing rehabilitation was provided. Body weight (BW); fiberoptic endoscopic evaluation of swallowing (FEES), functional oral intake scale (FOIS), and diet level; 10-item eating assessment tool (EAT-10), and MD Anderson Dysphagia Inventory (MDADI); and adherence at baseline, 1, 3, 6, 12, and 24 months were evaluated.

RESULTS: A total of 104 patients were included during May 2018 to July 2020. Compared to the baseline, significant deterioration in BW, FOIS, and MDADI was noted at one month. However, a trend of recovery was observed in FOIS from one month, and in BW and MDADI from three months. A total of 94% patients were free of tube feeding at 12 months but with a diet requiring special preparations or compensation. Safe swallowing could be achieved in approximately 90% of the participants after six months with diet modification or compensatory maneuvers. BW at 18 and 24 months did not differ significantly fr om baseline.

CONCLUSION: Proactive swallowing therapy is feasible for patients with locally advanced oral cancer receiving definitive treatments. It facilitates safe oral intake and adequate nutrition. Patients who performed swallowing exercises had a faster and better recovery in swallowing function and swallowing-related QoL.

PMID:34656054 | DOI:10.1016/j.oraloncology.2021.105569

View on the web

GLI-1 polymorphisms of Hedgehog pathway as novel risk and prognostic biomarkers in melanoma patients

xlomafota13 shared this article with you from Inoreader

SocialThumb.00008390.DC.jpeg

Objective In adult organisms, deregulation of the sonic hedgehog (SHH) signaling pathway is significantly correlated with different malignancies. Currently, data associating genetic polymorphisms in the SHH pathway with melanoma are scarce and largely unknown. The objective of our study was to elucidate an association between gene polymorphisms in the SHH pathway and prognosis of melanoma skin cancer patients. Methods The current study investigated the association of PTCH1 (rs357564), SMO (rs2228617) and GLI1 (rs2228224, rs2228226), polymorphisms with melanoma predisposition and prognosis. Single-nucleotide polymorphisms were assessed by TaqMan SNP Genotyping Assays. The study involved 93 melanoma patients and 97 individuals in the control group. Results Melanoma patients with the variant mutant genotype GG of GLI1 rs2228226 polymorphism had poorer overall survival and recurrence-free survival (P = 0.0001 and P = 0.037, respectively). The multivariate analysis revealed that disease progression [hazard ratio (HR) = 14.434, P = 0.0001] and the GLI1 rs2228226 polymorphism (HR = 4.161, P = 0.006) persisted as independent prognostic factors. Mutated allele carriers (combined heterozygous and mutated genotypes) for GLI1 rs2228224 G and GLI1 rs2228226 G allele significantly increased melanoma risk [odds ratio (OR) = 2.261, P = 0.007; OR = 2.176, P = 0.010]. Conclusion Our study demonstrated that genetic variants in GLI1, downstream member of the HH signaling pathway, are the risk factors for melanoma susceptibility and it can be a novel marker for melanoma prognosis. As a crucial SHH signaling member, GLI1 can also be regarded as a novel drug target for anti-cancer treatment in melanoma. * Marija Dunjic and Nikola Lukic contributed equally to the writing of this article. Received 13 August 2021 Accepted 16 September 2021 Correspondence to Gordana Supic, PhD, Associate Professor, Medical Faculty of Military Medical Academy, University of Defence, Crnotravska 17, 11000 Belgrade, Serbia, Tel: +381113608381; e-mail: gogasupic@gmail.com Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
View on the web

Πέμπτη 14 Οκτωβρίου 2021

The Substantial Omission of Postoperative Radiotherapy in Patients With Advanced-Stage Oral Cancer

xlomafota13 shared this article with you from Inoreader

jamanetwork.com

This cohort study aims to identify factors associated with omission of adjuvant postoperative radiotherapy in patients with advanced-stage oral squamous cell cancers in the US.
View on the web

Acute Vision Loss From IgG4-Related and Bacterial Rhinosinusitis After COVID-19

xlomafota13 shared this article with you from Inoreader

jamanetwork.com

This case report describes a man in his 70s who presented to the emergency department with a headache for 2 weeks and vision loss in the right eye for 2 days and was subsequently diagnosed with IgG4-related and Streptococcus constellatus rhinosinusitis.
View on the web

Continuous Local Anesthetic Wound Infusions as Postoperative Standard of Care in Patients With Head and Neck Cancer

xlomafota13 shared this article with you from Inoreader

jamanetwork.com

To the Editor We thank Gostian et al for their study demonstrating a reduction in postoperative pain when continuous wound infusion (CWI) was used after head and neck oncological resections. The authors call for CWI to be assimilated into the multimodal postoperative analgesic concept in patients. However, prior to widespread implementation, we find it prudent to draw attention to a few caveats to the study's conclusions.
View on the web

Neoadjuvant PD-1/PD-L1 Inhibitors for Resectable Head and Neck Cancer

xlomafota13 shared this article with you from Inoreader

jamanetwork.com

This systematic review and meta-analysis assesses the efficacy and safety of neoadjuvant immunotherapy for resectable head and neck squamous cell carcinoma.
View on the web

Symptoms With New Loss of Taste or Smell in Adults With or Without SARS-CoV-2 Infection

xlomafota13 shared this article with you from Inoreader

Message:

There have been reports of loss of taste or smell associated with viral infections, including SARS-CoV-2. However, it is not clear whether these symptoms are more frequent in SARS-CoV-2 infection compared with other viral infections.1,2 Prior studies among individuals with SARS-CoV-2 infection suggest loss of taste or smell occurs early in the disease course and is associated with younger age, female sex, and milder disease.1,3-5 Those studies largely have not examined which symptoms occur with new loss of taste or smell. Identifying concomitant symptoms may guide future studies to identify a pattern of symptoms that form a unique clinical presentation. We therefore described which symptoms were reported with new loss of taste or smell among individuals with and without SARS-CoV-2 infection.

Methods
Data for this cross-sectional study were collected from the Centers for Disease Control and Prevention's Coronavirus Self-checker (online since March 2020), an online tool designed to assist users in deciding whether to seek testing or medical care per guidelines from possible SARS-CoV-2 exposure.6 Users selected hard-coded responses that included demographics (age, sex, race, ethnicity), any COVID-19 test results within the past 10 days (positive, negative), and symptoms (new loss of taste or smell, muscle aches or body aches, cough, mild or moderate difficulty breathing, fever, vomiting or diarrhea, headache, congestion or runny nose, sore throat, other). Vaccination status was not recorded. The sample included 59 153 completed uses of the tool occurring between February 2 and May 3, 2021, by US adults 18 years or older who reported test results. This study was reviewed by the Centers for Disease Control and Prevention (CDC), and its conduct was consistent with applicable feder al law and CDC policy (45 CFR §46, 21 CFR §56, 42 USC §241(d), 5 USC §552a, and 44 USC §3501 et seq). This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.

To evaluate the association between each symptom and new loss of taste or smell, multivariate logistic models estimated odds ratios (ORs) stratified by test positivity and adjusted for each demographic variable and symptom. For all statistical analyses, SAS, version 9.4 software (SAS Institute Inc) was used.

Results
The Table shows respondent characteristics from 59 153 completed uses of the tool. The largest age group was 18 to 29 years (15 792 [26.7%]), 38 798 (65.6%) were female, and 37 025 (62.6%) were non-Hispanic White respondents. Symptoms associated with new loss of taste or smell varied by SARS-CoV-2 test positivity (Figure). Among individuals with negative test results, congestion or runny nose was more strongly associated with loss of taste and smell (OR, 2.26 [95% CI, 2.08-2.45]) compared with those with positive test results (OR, 1.66 [95% CI, 1.54-1.79]). Among individuals with negative test results, cough and fever were significantly associated with new loss of taste or smell (cough: OR, 1.57 [95% CI, 1.45-1.69]; fever: OR, 1.16 [95% CI, 1.07-1.25]) but not among those with positive test results (cough: OR, 1.01 [95% CI, 0.94-1.09]; fever: OR, 0.95 [95% CI, 0.88-1.02]). Vomiting or diarrhea was more strongly associated with new loss of taste or smell among those with posit ive test results (OR, 1.52 [95% CI, 1.40-1.65] compared with those with negative test results (OR, 1.23 [95% CI, 1.13-1.35]).

Discussion
The findings of this cross-sectional study suggest that differences in symptoms occurring with new loss of taste or smell were seen between groups based on SARS-CoV-2 test positivity. In both groups, muscle aches or body aches, mild or moderate difficulty breathing, vomiting or diarrhea, and congestion or runny nose were associated with a new loss of taste or smell. However, in both groups with positive and negative test results, congestion or runny nose had strong associations with new loss of taste or smell, suggesting the latter may not be a valid marker of test positivity in this sample.

One particular strength of this study is the large sample of recent data. Limitations include possible residual confounding inherent in observational data and potential for data to partially reflect individuals who used the tool multiple times and/or had been vaccinated. There may also be selection bias from analyzing online data, as respondents were, on average, younger and more likely to be female compared with the general population. Users may also have been aware of loss of taste or smell as a symptom of COVID-19, which may have resulted in bias and/or loss of power. Further studies in other populations may elucidate whether symptoms accompanying a new loss of taste or smell may form part of a unique clinical presentation associated with a milder course of disease.

jamanetwork.com

This cross-sectional study uses data from the Centers for Disease Control and Prevention's Coronavirus Self-checker to assess which symptoms are reported with new loss of taste or smell among individuals with and without SARS-CoV-2.
View on the web

Αναζήτηση αυτού του ιστολογίου